Daehan New Pharm Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Daehan New Pharm's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2013 |
Recent past performance updates
Recent updates
Daehan New Pharm Co., Ltd.'s (KOSDAQ:054670) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 10
What Type Of Shareholders Own The Most Number of Daehan New Pharm Co., Ltd. (KOSDAQ:054670) Shares?
Feb 17Here's Why Daehan New Pharm (KOSDAQ:054670) Can Manage Its Debt Responsibly
Jan 21
If You Had Bought Daehan New Pharm's (KOSDAQ:054670) Shares Five Years Ago You Would Be Down 25%
Dec 31Is Daehan New Pharm Co., Ltd.'s(KOSDAQ:054670) Recent Stock Performance Tethered To Its Strong Fundamentals?
Dec 10In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Daehan New Pharm has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How Daehan New Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 13 | 54,475 | -4,005 | 25,568 | 0 |
| 30 Jun 13 | 52,832 | -3,960 | 24,871 | 0 |
Quality Earnings: Insufficient data to determine if A054670 has high quality earnings.
Growing Profit Margin: Insufficient data to determine if A054670's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A054670's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare A054670's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if A054670's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: A054670 has a negative Return on Equity (0%), as it is currently unprofitable.